Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis |
| |
| Affiliation: | 1. Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA;2. Department of Dermatology, Brigham and Women''s Hospital, Harvard Medical School, Boston, MA, USA;3. Department of Medicine, Division of Rheumatology, Brigham and Women''s Hospital, Harvard Medical School, Boston, MA, USA;4. Department of Dermatology, University of Colorado School of Medicine, Aurora, CO, USA;1. Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA;2. Department of Medicine, Division of Rheumatology, Weill Cornell Medicine, New York, NY, USA;3. Department of Medicine, Division of Rheumatology, University of Colorado Denver - Anschutz Medical Campus, Aurora, CO, USA |
| |
| Abstract: | Psoriasis and psoriatic arthritis are chronic inflammatory diseases affecting the skin and joints, respectively. Psoriasis and psoriatic arthritis are associated with a high comorbidity burden as well as negative impact on quality of life. Impact on health-related quality of life is optimized when both skin and joint manifestations are effectively treated. The identification of key cytokines involved in disease pathogenesis has led to the development of several therapeutic options for psoriatic disease. When selecting a therapy, it is important to consider disease severity, psoriasis disease subtypes or domains of psoriatic arthritis, comorbidities, patient preference for treatment, among other factors. This review summarizes current biologic and small molecule treatment options as well as emerging therapies for moderate-to-severe adult plaque psoriasis and psoriatic arthritis. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
